AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study for Observing Severe Asthma in Patients Treated With Tezepelumab
Recruiting
- Conditions
- Asthma
- Interventions
- Other: None (Observational Study)
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 550
- Registration Number
- NCT05677139
- Locations
- 🇨🇭
Research Site, Sion, Switzerland
LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)
Active, not recruiting
- Conditions
- Breast Cancer
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 61
- Registration Number
- NCT05677308
- Locations
- 🇯🇵
Research Site, Yamanashi, Japan
A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy Participants
Phase 1
Terminated
- Conditions
- Non-alcoholic Steatohepatitis
- Interventions
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 31
- Registration Number
- NCT05668936
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study
Recruiting
- Conditions
- Unresectable Hepatocellular Carcinoma
- First Posted Date
- 2022-12-28
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 300
- Registration Number
- NCT05667064
- Locations
- 🇯🇵
Research Site, Yamanashi, Japan
eVusheld Assessment reaL wORld Effectiveness at UPMC
- First Posted Date
- 2022-12-28
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4232
- Registration Number
- NCT05667116
- Locations
- 🇺🇸
Research Site, Pittsburgh, Pennsylvania, United States
Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study
Active, not recruiting
- Conditions
- Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma)
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 67
- Registration Number
- NCT05665374
- Locations
- 🇯🇵
Research Site, Yamanashi, Japan
eVusheld Assessment reaL wORld Effectiveness in the VA Health System
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5814
- Registration Number
- NCT05663957
- Locations
- 🇺🇸
Research Site, Salt Lake City, Utah, United States
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
Recruiting
- Conditions
- Pancreatic Cancer
- Interventions
- Drug: Non-GLP-1 RA based glucose lowering drugs
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24000
- Registration Number
- NCT05663515
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oral AZD6793 in Healthy and Chronic Obstructive Pulmonary Disease Participants, to Assess the Relative Oral Bioavailability Between Two Formulations, and the Food Effect on the PK of AZD6793 Compared to Fasting State.
- First Posted Date
- 2022-12-22
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 93
- Registration Number
- NCT05662033
- Locations
- 🇬🇧
Research Site, Wythenshawe, United Kingdom
Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study
Phase 2
Completed
- Conditions
- COVID-19, SARS-CoV-2
- Interventions
- Biological: AZD5156 (Parent study Sentinel Safety Cohort)Biological: Placebo (Parent study Sentinel Safety Cohort)Biological: EVUSHELD™ (Parent study Main Cohort)Biological: Placebo (Parent study Main Cohort)Biological: AZD3152 (Sub-study)Biological: AZD3152 (Parent study Main Cohort)
- First Posted Date
- 2022-12-13
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3882
- Registration Number
- NCT05648110
- Locations
- 🇻🇳
Research Site, Hochiminh city, Vietnam
© Copyright 2025. All Rights Reserved by MedPath